Integrase inhibitors can bind to polyvalent cations resulting in potentially clinically significant drug interactions with coadministered cation-containing antacids and other supplements/multivitamins. Management of such interactions often requires the temporal separation of the integrase inhibitor from the cation-containing product.
We have produced a new Prescribing Resource which gives a brief description of the nature of these interactions and summarises dosing recommendations (from European and American product labels and this website) when integrase inhibitors are coadministered with cation-containing products.
This document is available as a PDF in the Prescribing Resources section of the website.
